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DCs can either magnify or mute immu-
nity by sampling antigens throughout 
body and presenting them to lymphocytes 
in combination with secondary signals 
that either activate or tolerize the re-
sponding cell. This quality, which makes 
DCs a handy weapon against both cancer 
and autoimmune disease, spurred Caetano 
Reis e Sousa to dissect the pathways that 
control different DC functions.
Reis e Sousa first encountered DCs 
as a graduate student in Jonathan Aus-
tyn’s laboratory at Oxford University. 
At the time, these cells were thought to 
lack the ability to phagocytose anti-
gens—a troubling deficiency in cells 
known as the initiators of immune re-
sponses to microbes. 
Using DCs found in 
the skin, Reis e Sousa 
showed that the in-
ability to pick up an-
tigen was limited to 
mature cells; freshly 
isolated ("immature") 
DCs could engulf 
particulate antigens 
with ease (1).
Determined that 
his DC expertise be-
come more than skin-
deep, Reis e Sousa 
accepted a post-doc-
toral position with 
Ron Germain at the 
NIH, where he stud-
ied antigen processing 
and cross-presentation by DCs and other 
cells (2). While at the NIH, he also col-
laborated with Alan Sher to investigate 
how microbe-activated DCs induce a T 
helper (Th)-1 cell response (3).
Since starting his own laboratory at 
the London Research Institute in 1998, 
Reis e Sousa has defined several pathways 
of DC activation that involve Toll-like 
receptors (TLRs) and non-TLRs such as 
RIG-I and C-type lectins (4–7). His 
group recently discovered a marker for a 
DC subset adept at cross-presentation, 
which might help bring DCs further into 
the realm of translational medicine (8).
PATH TO DCS
When did you get interested in science?
I liked biology during my school years in 
Portugal, but never really got interested in 
it as a career until I went to high school at 
the United World College of the Atlantic 
in Wales. Like many people, I was begin-
ning to get a little philosophical at that 
age—wondering about the meaning of 
life and our place in the universe—that 
sort of thing. I thought biology would of-
fer good answers to these questions. Hav-
ing said that, my fi   rst thought was to 
study medicine, not biology.
What stopped you?
My academic counselor convinced me 
that medical school was not for me be-
cause I had misspelled "medicine" on 
the application!
A subliminal message! So how did you 
end up studying DCs?
After I fi  nished my undergraduate degree 
in London, I got a government-sponsored 
scholarship from Portugal that let me stay 
in the UK to do a PhD. I got accepted into 
a laboratory at Oxford, but it turned out to 
be the wrong choice. After three months 
there, I started desperately going around to 
every laboratory to see if I could switch, 
but everyone I talked to was suspicious of 
why I wanted to move. Fortunately for me, 
Jon Austyn was one person who didn’t 
have that attitude, and I happily started 
working with DCs in his laboratory.
A MATURING CAREER
Your thesis work showed the phagocytic 
nature of immature DCs. What was the 
impact of that fi  nding?
I think it reinforced the notion that DCs 
have an antigen acquisition stage followed 
by an antigen presentation stage. Our re-
sults from my work with Langerhans 
cells—a DC subset found in the skin—
came out in 1993 in the same issue of the 
JEM in which Ralph Steinman and Kayo 
Inaba published similar results using DCs 
from bone marrow progenitors.
What were your post-doctoral goals?
I particularly enjoyed the cell biological 
aspect of immunology—the antigen 
processing part. So I went to the NIH to 
work with Ron Germain, who is an ex-
pert on everything, including antigen 
processing, and who was then interested 
in working with Langerhans cells. But 
after spending my entire graduate career 
peeling ear sheets from hundreds of mice 
and separating the dermis from the epi-
dermis to isolate these cells, I was bored 
to tears and really didn’t want to touch 
them ever again.
Did Ron let you off   the hook?
Yes, I made a deal with him that I would 
come to his laboratory to work on any-
thing but Langerhans cells. Ron, being 
the extraordinary immunologist that he 
is, gave me the freedom to work on 
many diff  erent things. I fi  rst tried to un-
derstand how exogenous particulate an-
tigens get presented via the class I MHC 
pathway. The rule is that this pathway 
presents endogenous antigens, whereas 
the exogenous antigens get processed 
via the class II MHC pathway. But we 
knew of instances where this rule is bro-
ken, and so I studied antigen processing 
in macrophages to understand the cross-
presentation phenomenon.
Reis e Sousa is unraveling the pathways that regulate dendritic cell (DC) 
function in the hope of designing better vaccines and immunotherapies.
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NEW CONNECTIONS
How did your collaboration with Alan Sher 
come about?
Alan’s group at the NIH was studying 
how Th1 responses are initiated. Every-
one agreed that the cytokine IL-12 was 
essential, but many argued that only mac-
rophages produced IL-12 in response to 
microbes, whereas DCs did not. I’d al-
ready encountered this sort of argument 
in my graduate days when we’d disproved 
the idea that DCs couldn’t phagocytose 
microbial antigens.
I remember betting with Alan that 
immature DCs that encountered patho-
gens could produce IL-12. I was proved 
right when Alan injected mice with a 
prep of Toxoplasma and stained tissues 
for IL-12: all the cells that stained for 
cytokine turned out to be DCs. When 
we published this in 1997, it was effec-
tively the first demonstration that DCs 
can respond to microbial stimuli by pro-
ducing IL-12—an idea that is well es-
tablished today.
Did you continue to work on the 
DC/IL-12 story when you started your 
laboratory?
Yes. Others had found that DCs could 
also make IL-12 in response to CD40 
ligation, which made me wonder if these 
were independent mechanisms or if they 
somehow worked sequentially. We found 
that CD40 amplifi  ed the eff  ects of the 
Toxoplasma extract. This fi  nding suggest-
ed that a microbe interacts with a DC 
and sets it up for making a certain cyto-
kine profi  le, and then the CD40 ligand 
comes along as a neutral stimulus and 
amplifi  es the predetermined pattern.
To prove this idea, we went through 
all of the microbial stimuli that we could 
get our hands on and looked at their abil-
ity to induce two cytokines—IL-12 and 
IL-10—that were quite important at the 
time. We identified some stimuli that bi-
ased DCs toward IL-12 production and 
others such as yeast particles that triggered 
a lot of IL-10 secretion. This was when 
pattern recognition receptors such as 
TLRs were becoming interesting, but we 
found that the IL-10 response to yeast was 
not TLR-dependent. That’s what led us 
to define a TLR-independent pathway 
involving C-type lectin receptors.
Did you also continue to work on antigen 
cross-presentation through the years?
Yes. I began to think that the types of T 
cell responses one might want to get 
against tumors are exactly the responses 
one develops against viruses, and so I 
tried to understand how DCs sense vi-
ruses. We found that they use TLR7 
and RIG-I to detect single-stranded 
RNA viruses. At the same time, we 
started trying to use DC’s cross-prim-
ing ability to activate anti-tumor T cells 
via the class I pathway. CD8α+ DCs are 
particularly good at cross-presenting 
viral antigens and we found that they 
can sense virus-infected cells via TLR3. 
So we thought that loading these DCs 
with tumor antigens while activating 
them with TLR3 agonists and anti-
CD40 would be an optimal strategy 
against cancer.
To specifically target these DCs, we 
borrowed from the work of Ralph Stein-
man and Michel Nussenzweig, who ad-
vocate the use of antibodies to target DCs. 
We started to characterize molecules that 
would serve as tags and came up with 
DNGR1—a C-type lectin receptor—as a 
possible target on CD8α+ DCs. We’ve 
shown that immunizing mice with anti-
DNGR1 antibodies carrying tumor epit-
opes and an adjuvant leads to the 
destruction of melanoma tumors.
Have you found the receptor’s natural 
ligand?
Not yet. We’re now exploring its ability to 
respond to endogenous stimuli, which 
might explain circumstances in which im-
munity appears to take place in the absence 
of microbes. We are also trying to fi  nd ago-
nists for other C-type lectins because these 
receptors might be possible alternatives to 
TLRs in triggering immunity.
You wrote an essay recently, in which you 
stressed the importance of terminology in 
DC biology. What was the reason for 
this emphasis?
I think language illuminates thinking. And 
the way in which we employ terminology 
shapes the way we think. I realized this 
years ago when I gave a talk at my insti-
tute on TLR ligands triggering this and 
that. One of my colleagues, a structural 
biologist, asked me about the ligands’ af-
fi  nity for their receptors. I had to confess 
that we had no real 
biochemical proof that 
they were ligands be-
cause all we were doing 
was treating the cells 
with compound X and 
seeing whether it in-
duced a response or 
not. And in fact, the 
correct pharmacologi-
cal term that I should 
have used was “agonist,” 
because a ligand can 
also be an antagonist. Another case in 
point: no two immunologists use the 
word “tolerance” to mean the same thing! 
I work in an institute that’s mostly nonim-
munological, and I realize that many of 
my colleagues dislike immunologists, with 
good reason sometimes, because we are 
very wishy-washy with terminology.
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A CD8+ DC (blue) binds a dying, virus-
infected cell (red) and presents viral 
antigen to killer T cells.
“I think language 
illuminates 
thinking. And 
the way in which 
we employ 
terminology 
shapes the way 
we think.”